Long Acting Injectables Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Long Acting Injectables Market Trends and Insights

Improved Adherence and Relapse Prevention in Chronic Disease Management

Oral antipsychotic nonadherence affected nearly half of individuals with schizophrenia spectrum disorders and contributed significantly to inpatient psychiatric spending. The American Psychiatric Association recommended considering long-acting injectables (LAIs) earlier after a confirmed diagnosis, expanding the eligible patient population beyond those with documented oral treatment failure. A 2026 mirror-image study of 149 patients in Turkey associated LAI initiation with an 80% reduction in hospitalization hazard and an 83% reduction in relapse hazard compared with prior oral treatment periods.^{[1]Clinical Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia Spectrum Disorders,” BMC Psychiatry, link.springer.com} A 2025 EULAST trial analysis found that LAIs reduced the risk of all-cause discontinuation by 36% versus oral antipsychotics among individuals with early-phase schizophrenia and comorbid substance use disorder.^{[2]Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk,” CNS Drugs, link.springer.com}

Expansion of Long-Acting HIV Treatment and Pre-Exposure Prophylaxis

Long-acting HIV therapies evolved from specialized adherence solutions into established clinical options. The FDA approved Gilead’s twice-yearly Yeztugo (lenacapavir) for pre-exposure prophylaxis (PrEP) in June 2025, following the PURPOSE 1 and PURPOSE 2 trials, in which at least 99.9% of participants remained HIV-negative. ViiV Healthcare’s LATITUDE Phase III trial found that Cabenuva reduced the cumulative risk of regimen failure to 22.8%, compared with 41.2% for daily oral therapy among individuals with adherence challenges. The CDC’s 2025 clinical recommendation and ViiV Healthcare’s expanded Medicines Patent Pool license covering 133 countries supported access and clinical capacity development in Sub-Saharan Africa and South Asia.^{[3]Information About Medications for Opioid Use Disorder,” U.S. Food and Drug Administration, fda.gov}

Rising Need for Extended-Release Therapies in Opioid Use Disorder

Monthly injectable buprenorphine and extended-release intramuscular naltrexone reduced reliance on daily supervised dosing, which could create diversion risks, treatment fatigue, and adherence gaps. Long-acting formulations reduced clinic visits required solely for dosing and supported patient retention. A 2025 review found that the subcutaneous in-situ-forming depot technology used in Sublocade eliminated the need for daily clinic attendance and addressed a key barrier to treatment continuity. In July 2025, Virginia Medicaid unbundled reimbursement for certain LAIs from hospital daily rates, while the FDA’s listing of approved LAIs for opioid use disorder provided clearer guidance for prescribers.

Formulation Platforms Enabling Monthly-to-Six-Month Dosing Intervals

The long-acting injectables market was increasingly differentiated by formulations that maintained therapeutic drug concentrations for longer durations. Poly(lactic-co-glycolic acid) (PLGA) microspheres and in-situ-forming depot systems enabled dosing intervals ranging from two weeks to six months, with polymer properties determining release duration and initial release profiles. Teva and MedinCell used SteadyTeq copolymer technology in UZEDY and the investigational olanzapine LAI TEV-749; the FDA accepted its new drug application (NDA) in February 2026, and the European Medicines Agency accepted its marketing authorization application (MAA) in May 2026. Research published in 2025 achieved a drug loading of 293 mg/mL using self-aggregating microcrystals injectable through needles smaller than 25 gauge, while a 2026 study demonstrated cocrystal LAI suspension technology with tunable release profiles without proprietary polymer matrices.

High Acquisition Cost and Reimbursement Complexity

New LAIs may experience slow uptake despite strong clinical evidence, as regulatory approval does not ensure routine coverage. Yeztugo had a U.S. annual list price of USD 28,218, increasing focus on formulary decisions and patient access. CVS Caremark initially excluded Yeztugo from its commercial and ACA formularies during negotiations, delaying treatment initiation. The Medicare Part D benefit redesign under the Inflation Reduction Act changed plan incentives for high-cost LAI antipsychotics and may have increased the use of prior authorization or step therapy. The olanzapine pamoate REMS required 3-hour post-injection monitoring at a certified facility, increasing delivery costs, which TEV-749 aimed to avoid through its REMS-free design.

Manufacturing Scale-Up Risk for Sterile Suspensions and Complex Depots

Sterile LAI suspensions posed manufacturing and regulatory challenges that affected supply reliability and development timelines. Many microsphere and depot products could not undergo terminal sterilization, requiring aseptic processing, validated cleanrooms, controlled excipient supplies, and rigorous environmental monitoring. Studies found that inadequate control of milling temperature and homogenization energy could extend polymorphic instability from laboratory-scale to commercial aripiprazole monohydrate production. Gamma irradiation also degraded polymeric surfactants, including poloxamer and PEG, and caused irreversible caking after 18 months. These factors increased production costs and made specialized manufacturing capabilities a competitive requirement in the long-acting injectables market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Therapeutic Area: CNS Disorders Lead Revenue While Infectious Diseases Lead Growth

CNS disorders accounted for 45.23% of the long-acting injectables market in 2025, supported by the established use of antipsychotic LAIs for schizophrenia, schizoaffective disorder, and bipolar I disorder. Paliperidone palmitate is available in PP1M, PP3M, and PP6M formulations, supporting 1-, 3-, and 6-month treatment intervals. Otsuka’s and Alkermes’ aripiprazole LAI portfolios also serve the established psychiatric treatment population. These products support patient management from stabilization through long-term maintenance.

Infectious diseases are forecast to grow at a CAGR of 14.53% between 2026 and 2031, driven by HIV treatment and prevention. As of April 2026, the FDA had approved Cabenuva for administration every 1 to 2 months, Sunlenca every 6 months, and Yeztugo as a twice-yearly PrEP option. These dosing intervals expand patient and clinician options and extend LAI use beyond psychiatric treatment. Metabolic and endocrine disorders remain a stable therapeutic area, supported by LHRH agonist depots for hormone management in prostate and breast cancer. Camurus launched monthly subcutaneous octreotide, CAM2029, in Germany in late 2025 for acromegaly.

By Molecule Type: Small Molecules Retain Scale While Biologics Gain Momentum

Small molecules accounted for 78.55% of the long-acting injectables market in 2025. Their leadership reflects the maturity of antipsychotics, antiretrovirals, and LHRH agonists in controlled-release formulation development. PLGA microspheres and nanocrystal suspensions are well established for many active ingredients, while regulatory precedents remain more developed for small-molecule LAIs than for newer biologic depots.

Biologics are forecast to grow at a CAGR of 14.67% from 2026 to 2031. HIV broadly neutralizing antibody programs and emerging autoimmune LAI programs support this outlook. ViiV Healthcare’s Phase IIb EMBRACE study found that lotivibart, combined with monthly intramuscular cabotegravir, maintained viral suppression in 94% of intravenous recipients and 82% of subcutaneous recipients. These findings indicate that biologic delivery can support durable pharmacokinetic activity across multiple administration routes.

By Technology: Polymer-Based Depots Lead While In-Situ Depots Expand Faster

Polymer-based depot systems accounted for 42.45% of the long-acting injectables market in 2025. Their leadership reflects decades of use in antipsychotics, oncology hormone therapies, and antiretrovirals. Developers can adjust PLGA degradation through the lactide-to-glycolide ratio, molecular weight, and terminal group chemistry, supporting release durations from 2 weeks to 6 months.

Microsphere formulations differ primarily in particle design, while nanoformulations and nanocrystal suspensions are gaining traction for potent biologic and oncology payloads where PLGA microsphere encapsulation efficiency is insufficient. Liposomal systems, established in intravenous oncology, are also being adapted for subcutaneous depot applications. These technologies continue to support a broad product base in the long-acting injectables market. In-situ-forming depots are forecast to grow at a CAGR of 13.83% from 2026 to 2031. Growth is supported by the elimination of a separate microparticle manufacturing step, compatibility with subcutaneous delivery, and high drug-loading potential. MedinCell’s SteadyTeq technology supports Teva’s UZEDY and the investigational TEV-749 olanzapine formulation. In the SOLARIS Phase 3 trial, TEV-749 showed no post-injection delirium or sedation syndrome across 3,470 injections.

By Route of Administration: Intramuscular Delivery Leads While Subcutaneous Delivery Grows Faster

Intramuscular delivery accounted for 72.67% of the long-acting injectables market in 2025. This position reflects established clinical practice for antipsychotic LAIs administered through gluteal and deltoid protocols. Products such as INVEGA SUSTENNA and Cabenuva rely on intramuscular administration for controlled depot absorption. The route benefits from established administration processes and trained healthcare professionals across psychiatric and infectious disease settings.

Subcutaneous delivery is forecast to advance at a CAGR of 13.45% from 2026 to 2031. Growth is supported by efforts to address injection volume and local-tolerability limitations. The 2025 SLIM microcrystal research reported a drug loading of 293 mg/mL through sub-25G needles. This payload density can support subcutaneous administration for medicines that previously required intramuscular depots and can reduce the risk of inadvertent intravascular injection compared with gluteal intramuscular administration.

By End User: Hospitals Lead Administration While Ambulatory Care Expands

Hospitals accounted for 45.67% of the long-acting injectables market in 2025. Their leading role reflects the use of many antipsychotic LAIs at inpatient discharge to stabilize patients before outpatient transition. Hospital-based administration also remains important for REMS-restricted medicines requiring post-injection observation. Hospitals can coordinate prescribing, administration, monitoring, and immediate follow-up within a single setting.

Ambulatory care and physician offices are forecast to grow at a CAGR of 12.88% from 2026 to 2031. This growth follows the broader shift toward community-based chronic disease management. Virginia Medicaid’s July 2025 reimbursement change created a financial incentive to move LAI administration to ambulatory programs rather than retain it within hospital daily rates. The change covered serious mental illness and substance use disorder care in emergency department and inpatient settings. In the CAPTIVATE real-world study of 241 PrEP users, 89% of providers reported an overall positive view of administering CAB LA in outpatient settings.

Geography Analysis

North America accounted for 41.67% of the long-acting injectables market share in 2025. The region benefited from established specialty pharmacy infrastructure, buy-and-bill reimbursement under Medicare Part B, and a supportive regulatory environment. The FDA approved Yeztugo for twice-yearly HIV pre-exposure prophylaxis (PrEP) in June 2025 and accepted the new drug application for TEV-749, a long-acting injectable olanzapine formulation, in February 2026. Canada approved ABILIFY ASIMTUFII in January 2025, introducing a bimonthly aripiprazole option for schizophrenia and bipolar I disorder.

Europe was the second-largest geography, with Germany, the United Kingdom, France, Italy, and Spain serving as key commercial markets. The European Commission authorized Yeytuo for HIV prevention, extending access across European Union member states, Norway, Iceland, and Liechtenstein. Camurus launched Oczyesa, CAM2029, a monthly subcutaneous octreotide treatment, in Germany in November 2025, while the EMA accepted the marketing authorization application for TEV-749 in May 2026. Prior authorization delays, the Part D redesign, and payer requirements for demonstrated administration or safety benefits remained relevant across developed markets.

Asia-Pacific is forecast to grow at a CAGR of 14.22% from 2026 to 2031. China expanded healthcare infrastructure and domestic manufacturing capabilities, supported by biosimilar and innovative LAI development, while Japan’s aging population and outpatient psychiatric care focus supported longer treatment intervals. A 2026 study reported PP3M continuation rates consistent with clinical trial findings, and Australia approved Yeytuo for HIV PrEP in January 2026. South Korea may support regional LAI production, while the Middle East and Africa and South America offer incremental opportunities through access programs, hormonal LAIs, and generic antipsychotic depot formulations.